StockData

Korro Bio vs Seres Therapeutics

KRRO and MCRB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KRRO and MCRB compare

Korro Bio is the larger company, worth 13 times as much as Seres Therapeutics ($187M against $14.0M).

Seres Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1193% compared with −4477% at Korro Bio.

Seres Therapeutics scores higher on the StockData Score (6 against 5 for Korro Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKRROMCRB
Size and price
Market cap$187M$14.0M
Share price$12.71$1.41
Change, 1 year95.5%−91.6%
Change, 5 years−95.5%−99.2%
Beta (5Y)2.430.28
Employees5866
StockData Score
Total score56 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score55
Dividend score00
Valuation
P/S78.6×7.4× (better)
P/B–0.4×
FCF yield−36.5% (better)−366%
Growth
Revenue growth (TTM)−62.1%–
Revenue growth, 5Y average−29.6% (better)−52.7%
Net income growth (TTM)–−126%
EPS growth (TTM)–−121%
Profitability
Operating margin−4625%−4463% (better)
Net margin−4477%−1193% (better)
FCF margin−2866%−2724% (better)
Return on equity–−66.6%
Financial health
Debt / equity–0.00
Current ratio9.55 (better)2.11
Altman Z-score−3.17 (better)−15.93
Piotroski F-score26 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%22.9%
Held by insiders27.4%2.3%
Insider net buying, 12 months$15.0M (better)−$10.0K
Short interest, % of float16.4%3.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.